Th17 cell durability offers promise for next-generation adoptive cancer immunotherapy trials – News-Medical.net
|
Th17 cell durability offers promise for next-generation adoptive cancer immunotherapy trials
News-Medical.net Medical University of South Carolina (MUSC) investigators report that long-term expansion protocols for adoptive cancer immunotherapy do not compromise Th17 cells' effectiveness against large tumors, in the March 9, 2017 issue of JCI Insight. This … |
